At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 24-Week,Int.,Rand.,Double-blind,Parallel-group,Multi-centre, Plac.-Controlled Phase III Study With a 24-Wk Ext.Per.to Eval.the Efficacy and Safety of Dapagliflozin in Comb.With Glimepiride (a Sulphonylurea) in Subjects With Type2 Diab.Who Have Inadeq. Glycaemic Control on Glimepiride Therapy Alone
In Brief
A Phase 3 clinical trial evaluating dapagliflozin, Glimepiride, and 3 other interventions for Type 2 Diabetes. Completed, enrolled 597 participants across 66 sites in 7 countries.
Detailed Summary
This study is being carried out to see if dapagliflozin in addition to glimepiride (sulphonylurea) is effective and safe in treating patients with type 2 diabetes when compared to glimepiride alone.
Study Details
Timeline
Interventions
tablet oral 2.5, 5, or 10 mg total daily dose once daily 48 weeks
tablet oral 2.5, 5, or 10 mg total daily dose once daily 48 weeks
rescue medication oral dosing in accordance with the manufacturer's recommendations and clinical practice
rescue medication oral dosing in accordance with the manufacturer's recommendations and clinical practice
rescue medication oral dosing in accordance with the manufacturer's recommendations and clinical practice